Repligen (FRA:RGN) Long-Term Debt : €501.9 Mil (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Repligen Long-Term Debt?

Repligen's Long-Term Debt for the quarter that ended in Dec. 2024 was €501.9 Mil.

Repligen's quarterly Long-Term Debt declined from Jun. 2024 (€481.0 Mil) to Sep. 2024 (€470.0 Mil) but then increased from Sep. 2024 (€470.0 Mil) to Dec. 2024 (€501.9 Mil).

Repligen's annual Long-Term Debt increased from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€467.8 Mil) and increased from Dec. 2023 (€467.8 Mil) to Dec. 2024 (€501.9 Mil).

Repligen Long-Term Debt Historical Data

The historical data trend for Repligen's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Long-Term Debt Chart

Repligen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

467.80

501.92

Repligen Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															467.80	472.81	480.97	469.97	501.92

Repligen (FRA:RGN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Repligen Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Repligen's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Repligen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

RGEN:USA RGN:Germany

Address

41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453

Website

https://www.repligen.com

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen Headlines

No Headlines